BWAY250117P12500
- 0.00
- 0.000.00%
Brainsway Newsroom
BrainsWay Reports Independent Pilot Data On Accelerated Deep TMS Treatment Of Alcohol Use Disorder
Express News | Brainsway Reports Positive Independent Pilot Data on Accelerated Deep Tms Treatment of Alcohol Use Disorder
BrainsWay's Deep TMS Shows Promise in Pain Reduction
BrainsWay Announces The Publication Of Feasibility Clinical Data Evaluating The Analgesic Effects Of Deep Transcranial Magnetic Stimulation In Patients With Peripheral Neuropathic Pain. The Results Were Published In The Neuromodulation Journal, In A...
Express News | Brainsway Reports Promising Feasibility Data Showing Pain Reduction With Deep Tms Therapy
Express News | Jonathan Shulkin Reports 19.1% Stake in Brainsway Ltd as of Nov 5 - SEC Filing
Ladenburg Thalmann Maintains Brainsway(BWAY.US) With Buy Rating, Raises Target Price to $13.4
Brainsway Price Target Raised to $13.40 From $12.60 at Ladenburg
BrainsWay Ltd. (BWAY) Q3 2024 Earnings Call Transcript
BrainsWay GAAP EPS of $0.02 Beats by $0.01, Revenue of $10.5M Beats by $0.41M
Express News | Brainsway Ltd: Increasing Full-Year 2024 Rev Guidance to Between $40 Mln to $41 Mln
Earnings Preview: Brainsway to Report Financial Results Pre-market on November 12
BrainsWay Secures $20 Million in Strategic Investment
Relief Mental Health Expands to Middleton, Wisconsin, Bringing Advanced Mental Health Treatments to the Madison Area
BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024
Does Brainsway (BWAY) Have the Potential to Rally 34.38% as Wall Street Analysts Expect?
Express News | Northland Capital Markets Maintains Outperform on BrainsWay, Raises Price Target to $12.5
BrainsWay Schedules Crucial Shareholders Meeting
What's Going On With BrainsWay Shares Monday?
BrainsWay Makes Deal With Valor, Shares Vault